NCT01885260 - Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

November 30, 2014

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ISIS-GCGRRx - Dose Level 1

3 doses on alternate days during the first week and then once weekly for 12 weeks

DRUG

ISIS-GCGRRx - Dose Level 2

3 doses on alternate days during the first week and then once weekly for 12 weeks

DRUG

Placebo

3 doses on alternate days during the first week and then once weekly for 12 weeks

Trial Locations (24)

1818

Isis Investigational Site, Soweto

1829

Isis Investigational Site, Lenasia South

4091

Isis Investigational Site, Durban

7130

Isis Investigational Site, Western Cape

7500

Isis Investigational Site, Parow, Cape Town

7700

Isis Investigational Site, Cape Town

30066

Isis Investigational Site, Marietta

32720

Isis Investigational Site, DeLand

33143

Isis Investigational Site, Miami

33306

Isis Investigational Site, Fort Lauderdale

35216

Isis Investigational Site, Birmingham

35662

Isis Investigational Site, Muscle Shoals

45245

Isis Investigational Site, Cincinnati

73103

Isis Investigational Site, Oklahoma City

77450

Isis Investigational Site, Katy

78404

Isis Investigational Site, Corpus Christi

84107

Isis Investigational Site, Salt Lake City

89101

Isis Investigational Site, Las Vegas

90057

Isis Investigational Site, Los Angeles

91710

Isis Investigational Site, Chino

92801

Isis Investigational Site, Anaheim

97404

Isis Investigational Site, Eugene

98057

Isis Investigational Site, Renton

99202

Isis Investigational Site, Spokane